login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
CONTEXT THERAPEUTICS INC (CNTX) Stock News
USA
- NASDAQ:CNTX -
US21077P1084
-
Common Stock
1.21
USD
-0.06 (-4.72%)
Last: 10/22/2025, 8:23:30 PM
1.24
USD
+0.03 (+2.48%)
After Hours:
10/22/2025, 8:23:30 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
CNTX Latest News, Press Relases and Analysis
All
Press Releases
17 days ago - By: Context Therapeutics Inc.
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
17 days ago - By: Context Therapeutics Inc.
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
20 days ago - By: Context Therapeutics Inc.
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20 days ago - By: Context Therapeutics Inc.
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
6 months ago - By: Context Therapeutics Inc.
Context Therapeutics Announces Chief Medical Officer Transition
21 days ago - By: Benzinga
- Mentions:
SNPS
CRSR
ABSI
TBCH
This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
2 months ago - By: Context Therapeutics Inc.
Context Therapeutics to Participate in Upcoming Investor Conferences
2 months ago - By: Context Therapeutics Inc.
Context Therapeutics to Participate in Upcoming Investor Conferences
3 months ago - By: Context Therapeutics Inc.
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
3 months ago - By: Context Therapeutics Inc.
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
5 months ago - By: Benzinga
- Mentions:
RGC
APDN
SNTI
HSDT
...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
5 months ago - By: Context Therapeutics Inc.
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
5 months ago - By: Context Therapeutics Inc.
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
5 months ago - By: Context Therapeutics Inc.
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
5 months ago - By: Context Therapeutics Inc.
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
5 months ago - By: Context Therapeutics Inc.
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 months ago - By: Context Therapeutics Inc.
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6 months ago - By: Context Therapeutics Inc.
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
6 months ago - By: Context Therapeutics Inc.
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
6 months ago - By: Context Therapeutics Inc.
Context Therapeutics Announces Chief Medical Officer Transition
6 months ago - By: Context Therapeutics Inc.
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
6 months ago - By: Context Therapeutics Inc.
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
7 months ago - By: Context Therapeutics Inc.
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
7 months ago - By: Context Therapeutics Inc.
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
7 months ago - By: Context Therapeutics Inc.
Context Therapeutics to Participate in Upcoming Investor Conferences
7 months ago - By: Context Therapeutics Inc.
Context Therapeutics to Participate in Upcoming Investor Conferences
7 months ago - By: Context Therapeutics Inc.
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
7 months ago - By: Context Therapeutics Inc.
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
7 months ago - By: Context Therapeutics Inc.
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
7 months ago - By: Context Therapeutics Inc.
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
8 months ago - By: Context Therapeutics Inc.
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8 months ago - By: Context Therapeutics Inc.
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8 months ago - By: Context Therapeutics Inc.
Context Therapeutics to Participate in Upcoming Investor Conferences
8 months ago - By: Context Therapeutics Inc.
Context Therapeutics to Participate in Upcoming Investor Conferences
Please enable JavaScript to continue using this application.